Valiant™ thoracic stent graft with Captivia™ delivery system
for Thoracic Endovascular Aortic Repair (TEVAR)
The Valiant™ Captivia™ stent graft system is designed to treat all lesions of the descending thoracic aorta, including thoracic aortic aneurysms (TAA), type B aortic dissection (TBAD), intramural hematoma (IMH), penetrating atherosclerotic (PAU), and blunt thoracic aortic injury (BTAI).
Overview
Product details
Deploy durability with Valiant™ Captivia™ system
Valiant™ Captivia™ thoracic stent graft system maintains vessel wall apposition and fixation, regardless of angulation and oversizing.1 Clinically supported by low type Ia endoleak rate (0% at 5 years).2 The stent graft system has over a decade of worldwide experience and has been chosen for over 150,000† patients worldwide. It has five years of clinical data across all descending thoracic aortic pathologies.2–4
Case image courtesy of Dr. Roy M. Fujitani, M.D.
The Valiant™ Captivia™ stent graft is the only device that maintains complete apposition regardless of angulation and oversizing.1
Results
The Valiant™ Captivia™ stent graft system remained apposed to the aortic wall at each increment of neck angulation and degree of oversizing in a simulated environment.
For the other stent grafts tested, lack of device wall apposition was observed between the proximal anchorage segment and the inferior aortic wall.
Angular flexibility and radial strength give the Valiant™ Captivia™ stent graft conformability and optimal seal1
† 10–19% device oversizing.
Risks associated with TEVAR procedures may include rupture, conversion to open repair, or secondary procedures.
| Product tested | Proximal apposition at different landing zone angulation | Body apposition at different landing zone angulation |
|---|---|---|
| Medtronic Valiant™ Captivia™ system | No lack of apposition (remained apposed) | No lack of apposition (remained apposed) |
| A | Lack of apposition above 120º | No lack of apposition (remained apposed) |
| B | No lack of apposition (remained apposed) | Lack of apposition above 110º |
| C | Lack of apposition above 110º | No lack of apposition (remained apposed) |
Test data not indicative of clinical performance.
Features
How does Valiant™ Captivia™ system maintain a continuous seal in a dynamic environment?
Achieving and maintaining a continuous seal is critical for TEVAR durability.
- The Valiant™ Captivia™ system establishes and maintains a continuous seal and optimizes apposition in a dynamic environment.
- It is the only device that maintains complete vessel wall apposition regardless of angulation and oversizing.1
Continuous seal
- Eight peak proximal stent design ensures even distribution of radial force for complete vessel wall apposition.
- Mini support spring enhances proximal apposition and seal.
Ease of access
- Crossing profile is similar to or lower than other thoracic stent grafts for ease of access.
- Hydrophilic coating facilitates stent graft delivery.
Precise deployment
- Platinum-iridium Figur8 markers provide high visibility for accurate placement.
- Three-step deployment with tip capture release provides controlled deployment and precise placement in the thoracic aorta.
Step 1
Slow, controlled deployment for precise placement
Step 2
Quick deployment option, if desired
Step 3
Tip capture release
- Absence of a longitudinal bar allows for enhanced flexibility and kink resistance.
- Broad selection of proximal and distal components leads to many combinations to customize for a variety of patients.
Physicians’ perspectives
Clinician experiences with Valiant™ Captivia™ video - (03:46)
Watch this video to hear leading clinicians discuss why they choose the Valiant™ Captivia™ stent graft system for their patients.
More information (see more)
Less information (see less)
Dr. Frank Arko accuracy video - (03:15)
See how the three-step Captivia™ delivery system enables simple graft adjustment and precise placement within the thoracic aorta.
More information (see more)
Less information (see less)
Dr. Jean Panneton conformability video - (03:41)
Watch this video and hear Dr. Panneton discuss how Valiant™ Captivia™ is highly flexible and conformable due to its sinusoidal shape, super‑elastic nitinol springs, and lack of a longitudinal bar.
More information (see more)
Less information (see less)
Dr. Hitoshi Matsuda dissection video - (02:50)
Watch this video and hear Dr. Matsuda review a type B aortic dissection case he treated with TEVAR, which provides a minimally invasive alternative to open surgical repair.
More information (see more)
Less information (see less)
Indications
The Valiant™ thoracic stent graft with the Captivia™ delivery system is indicated for the endovascular repair of all lesions of the descending thoracic aorta (DTA) in patients having the appropriate anatomy, including:
- Iliac or femoral artery access vessel morphology that is compatible with vascular access techniques, devices, or accessories;
- Nonaneurysmal aortic diameter in the range of 18 mm to 42 mm (fusiform and saccular aneurysms/penetrating ulcers), or 18 mm to 44 mm (blunt traumatic aortic injuries) or 20 mm to 44 mm (dissections); and
- Nonaneurysmal aortical proximal and distal neck lengths ≥ 20 mm (fusiform and saccular aneurysms/penetrating ulcers), landing zone ≥ 20 mm proximal to the primary entry tear (blunt traumatic aortic injuries, dissections). The proximal extent of the landing zone must not be dissected.
Manuals and technical guides
Instructions for use
Find this technical manual in the Medtronic Manual Library, in the product labeling supplied with each device, or by calling 877-526-7890.
Model specifications
Downloads
Related pages
Aortic catalog
Choose from a complete portfolio of market-leading aortic vascular therapies to treat aneurysm disease.
Educational resources on Medtronic Academy
Find additional information along with a variety of educational resources and tools.
† Data on file. Internal global finance report, total Valiant™ Captivia™ cases.
1. Canaud L, Cathala P, Joyeux F, Branchereau P, Marty-Ané C, Alric P. Improvement in conformability of the latest generation of thoracic stent grafts. J Vasc Surg. 2013;57(4):1084–1089. doi: 10.1016/j.jvs.2012.09.019
2. Conrad MF, Tuchek J, Freezor R, Bavaria J, White R, Fairman R. Results of the VALOR II trial of the Medtronic Valiant thoracic stent graft. J Vasc Surg. 2017;66(2):335–342. doi: 10.1016/j.jvs.2016.12.136.
3. Bavaria JE, Brinkman WT, Hughes GC, et al. Five-year outcomes of endovascular repair of complicated acute type B aortic dissections. J Thorac Cardiovas Surg. 2022;163(2):539–548.e2. doi: 10.1016/j.jtcvs.2020.03.162.
4. Patal HJ, Azizzadeh A, Matsumoto AH, et al. Five-year outcomes from the United States pivotal trial of Valiant Captivia stent graft for blunt aortic injury. Ann Thorac Surg. 2020;110(3):815–820. doi: 10.1016/j.athoracsur.2019.12.028.